IP Verse

Composition For Preventing And Treating Neuodegenerative Diseases Ad Cognitive Disorders - EP3219306

The patent EP3219306 was granted to FB Health on Nov 16, 2022. The application was originally filed on Mar 15, 2017 under application number EP17161008A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3219306

FB HEALTH
Application Number
EP17161008A
Filing Date
Mar 15, 2017
Status
Granted And Under Opposition
Oct 14, 2022
Grant Date
Nov 16, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SIFIAug 14, 2023SCHIWECK WEINZIERL KOCH PATENTANWALTE PARTNERSCHAFT MBBADMISSIBLE

Patent Citations (7) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
OPPOSITIONEP3130336
OPPOSITIONWO2004058258
SEARCHUS2003114415
SEARCHUS2010130537
SEARCHUS2012316128
SEARCHUS6015835
SEARCHWO2007049098

Non-Patent Literature (NPL) Citations (20) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- AISEN PS; GAUTHIER S; FERRIS SH ET AL., "Tramiprosate in mild-tomoderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)", ARCH MED SCI, (2011), vol. 1, pages 102 - 11-
DESCRIPTION- ALVAREZ-SABIN J; ORTEGA G; JACAS C; SANTAMARINA E; MAISTERRA 0; RIBO M; MOLINA C; QUINTANA M; ROMAN GC, "Long-term treatment with citicoline may improve poststroke vascular cognitive impairment", CEREBROVASC DIS., (2013), vol. 35, no. 2, pages 146 - 54-
DESCRIPTION- ALVAREZ-SABM J; ROMAN GC, "Citicoline in vascular cognitive impairment and vascular dementia after stroke", STROKE, (201101), vol. 42, no. 1, pages S40 - 3-
DESCRIPTION- CAO, G. ET AL., FREE RADIC. BIOL. MED., (1993), vol. 14, no. 3, pages 303 - 11-
DESCRIPTION- COTRONEO AM; CASTAGNA A; PUTIGNANO S; LACAVA R; FANT6 F; MONTELEONE F; ROCCA F; MALARA A; GARERI P, "Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study", CLIN INTERV AGING., (2013), vol. 8, pages 131 - 7-
DESCRIPTION- GARCFA-COBOS R; FRANK-GARCFA A; GUTIERREZ-FERNANDEZ M; DFEZ-TEJEDOR E, "Citicoline, use in cognitive decline: vascular and degenerative", J NEUROL SCI., (20101215), vol. 299, no. 1-2, pages 188 - 92, XP027526285-
DESCRIPTION- GHISELLI, A.; ET AL., FREE RADIC. BIOL. MED., (1995), vol. 18, no. 1, pages 29 - 36-
DESCRIPTION- GREENBERG SM; ROSAND J; SCHNEIDER AT ET AL., "A phase 2 study of tramiprosate for cerebral amyloid angiopathy", ALZHEIMER DIS ASSOC DISORD, (2006), vol. 20, pages 269 - 74-
DESCRIPTION- GRUBER SA; SAGAR KA; DAHLGREN MK; GONENG A; CONN NA; WINER JP; PENETAR D; LUKAS SE., "Citicoline Treatment Improves Measures of Impulsivity and Task Performance in Chronic Marijuana Smokers: A Pilot BOLD fMRI Study", INT J NEUROL NEUROTHER., (20150930), vol. 2, no. 3, pages 1 - 8-
DESCRIPTION- SAUMIER D; AISEN PS; GAUTHIER S ET AL., "Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer's disease: the ALZHEMED (tramiprosate) experience", J NUTR HEALTH AGING, (2009), vol. 13, pages 370 - 2-
DESCRIPTION- SAUMIER D; DUONG A; HAINE D; GARCEAU D; SAMPALIS J., "Domainspecific cognitive effects of tramiprosate in patients with mild to moderate Alzheimer's disease: ADAS-cog subscale results from the Alphase Study", J NUTR HEALTH AGING, (2009), vol. 13, pages 808 - 12-
DESCRIPTION- SPALLETTA G; CRAVELLO L; GIANNI W; PIRAS F ET AL., "Homotaurine Effects on Hippocampal Volume Loss and Episodic Memory in Amnestic Mild Cognitive Impairment", J. ALZHEIMERS DIS., (2016), vol. 50, no. 3, pages 807 - 16-
DESCRIPTION- TALLARIDA RJ, "Drug Synergism: its detection and applications", J PHARMACOLEXPTHER., (200109), vol. 298, no. 3, pages 865 - 72, XP007918154-
DESCRIPTION- WAYNER, D. D ET AL., FEBS LETT., (1985), vol. 187, no. 1, pages 33 - 7-
DESCRIPTION- ZAFONTE RD; BAGIELLA E; ANSEL BM; NOVACK TA; FRIEDEWALD WT; HESDORFFER DC; TIMMONS SD; JALLO J; EISENBERG H; HART T, "Effect of citicoline on functional and cognitive status among patients with traumatic brain injury: Citicoline Brain Injury Treatment Trial (COBRIT)", JAMA, (20121121), vol. 308, no. 19, pages 1993 - 2000-
DESCRIPTION- KNOTT V; DE LA SALLE S; SMITH D; CHOUEIRY J; IMPEY D; SMITH M; BEAUDRY E; SAGHIR S; LLIVITSKY V; LABELLE A, "Effects of acute CDP-choline treatment on resting state brain oscillations in healthy volunteers", NEUROSCI LETT., (20150330), vol. 591, doi:doi:10.1016/j.neulet.2015.02.032, pages 121 - 5, XP029204562
DESCRIPTION- GERVAIS F; PAQUETTE J; MORISSETTE C ET AL., "Targeting A? peptide with tramiprosate for the treatment of brain amyloidosis", NEUROBIOL AGING, (2007), vol. 28, doi:doi:10.1016/j.neurobiolaging.2006.02.015, pages 537 - 47, XP005901142
EXAMINATION- SERGIO DAVINELLI ET AL, "Cytoprotective Effects of Citicoline and Homotaurine against Glutamate and High Glucose Neurotoxicity in Primary Cultured Retinal Cells", OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, US, (20170101), vol. 2017, doi:10.1155/2017/2825703, ISSN 1942-0900, pages 1 - 7, XP055733693
OPPOSITION- SERGIO DAVINELLI et al., "Cytoprotective effects of citicoline and homotaurine against glutamate and high glucose neurotoxicity in primary cultured retinal cells", Hindwai, Oxidative Medicine and Cellular Longevity, vol. 2017, doi:10.1155/2017/2825703, pages 1 - 7, XP055733693
SEARCH- Judes Poirier ET AL, "Pharmacogenomics and the Treatment of Sporadic Alzheimers Disease:A Decade of Progress", Current Pharmacogenomics and Personalized Medicine, doi:10.2174/187569208784017494, (20080301), pages 63 - 76, URL: http://adgen.myasustor.com/index_htm_files/Current%20Pharmacogen%20Pers%20Med%206_63.pdf, (20161028), XP055315182 [A] 1-10 * page 71, column l, paragraph 3 * * page 71, column l, paragraph 4 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents